Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders

Oct 2023| PHM118B| BCC Publishing
Sample Report

Report Highlights

The global progressive ataxia and weakness disorders market reached $32.0 billion in 2022, should reach $35.1 billion by 2023 and $57.2 billion by 2028 with a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2023-2028.

Report Includes

  • 34 data tables and 34 additional tables
  • A comprehensive overview of the current and future global markets for the treatments of progressive ataxia and weakness disorders
  • Analyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024 and 2026, and projections of compound annual growth rates (CAGRs) through 2028
  • In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall market
  • Estimation of the actual market size and revenue forecast for global progressive ataxia and weakness disorders treatments market in USD million values, and corresponding market share analysis based on product, technology, disease type, application, distribution channel, and region
  • Discussion of the applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology
  • Identification of critical medical and geographical challenges as well as economic and demographic factors affecting the market growth
  • Review of key patent grants and recent patent applications on neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets, along with emerging technologies and new developments
  • Coverage of recent merger and acquisition (M&A) activities, venture fundings, and other impactful growth strategies in the global market neurodegenerative (i.e., progressive ataxia and weakness) disorders
  • Identification of the key players operating in the market, and analysis of their competitive landscape based on recent developments, segmental revenues, and operational integration
  • Company profiles of major players within the industry, including Abbott Laboratories, Glenmark Life Sciences, Novartis AG, Pfizer Inc., Roche Holding Ltd., and Sanofi

Report Scope

The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, the technologies involved, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, Canada and Australia. The report informs all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this helpful.

This report also covers merger and acquisition (M&A) strategies and collaborations, as well as the strengths and weaknesses of each strategy type.

Frequently Asked Questions (FAQs)

The progressive ataxia and weakness disorders drug market is projected to grow from $32.0 billion in 2022 to $57.2 billion in 2028, at a compound annual growth rate (CAGR) of 10.2 % during the forecast period.
The key factors driving the growth of treatments for syndromes of progressive ataxia and weakness disorders- Global Market include:
  • Increasing Prevalence of Neurological Disorders including Progressive Ataxia and Weakness Disorders and Awareness
  • Technological advancements and product launch
  • Increasing Expenditures for Health Care and investments for treatment for syndrome of Progressive Ataxia and Weakness Disorders
  • Rise in alcohol and drug usage
In this report, the market is segmented based on type, technology, diseases, region and distributive channel. Based on the type, the market is segmented into progressive ataxia and progressive weakness disorders. Based on the technology, the market is segmented as small molecule, monoclonal antibody and others. Based on diseases, progressive ataxia is segmented as Friedreich ataxia, Machado Joseph disease/SCA3 and Gertsmann Straussler Scheinker diseases and progressive weakness disorders as multiple sclerosis, hereditary neuropathies, amyotrophic lateral sclerosis, progressive bulbar palsy and hereditary spastic paraplegia. Based on distributive channel, the market is segmented into retail pharmacy, hospital pharmacy and online pharmacy.
Progressive weakness disorders will dominate the market by the end of 2028.
The major players in the market are Novartis AG, Pfizer Inc., Sanofi, Roche Holding Ltd. And Teva Pharmaceuticals.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $32.0 billion
Market size forecast $57.2 billion
Growth rate CAGR of 10.2% for the forecast period of 2023-2028
Units considered $ Millions
Segments covered Technology, Disease Type, Disease, Distributive Channel,
Regions covered North America, Europe, Asia-Pacific, Rest of the World (RoW)
Key Market Drivers
  • Progressive Ataxia and Weakness: Increasing Prevalence and Awareness
  • Technological Advancements and Product Launch
  • Increasing Expenditures for Health Care
  • Rise in Alcohol and Drug Use
Companies studied
  • ABBOTT LABORATORIES
  • ACORDA THERAPEUTICS INC.
  • AMERICAN REGENT INC.
  • APOTEX INC.
  • APOTHECA INC.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA GMBH
  • BAXTER INTERNATIONAL INC.
  • BRISTOL-MYERS SQUIBB
  • EISAI CO. LTD.
  • ELI LILLY AND COMPANY
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE PLC
  • GLENMARK LIFE SCIENCES
  • JOHNSON & JOHNSON
  • MERCK KGAA
  • NOVARTIS AG
  • PFIZER INC.
  • ROCHE HOLDING LTD.
  • SANOFI
  • TAKEDA PHARMACEUTICAL CO. LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
. Title/Chapter NamePagesPrice Member Price
Full Report: Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders180 $5,500 Free
Chapter- 1: Introduction8Free DownloadFree
Chapter- 2: Summary and Highlights5$250Free
Chapter- 3: Market Overview7$219Free
Chapter- 4: Market Dynamics8$250Free
Chapter- 5: Market Breakdown by Type and Technology14$438Free
Chapter- 6: Market Breakdown by Disease22$688Free
Chapter- 7: Market Breakdown by Region21$656Free
Chapter- 8: Market Breakdown by Distribution Channel6$188Free
Chapter- 9: Emerging Technologies and Developments5$156Free
Chapter- 10: ESG Development11$344Free
Chapter- 11: Patent Analysis6$188Free
Chapter- 12: M&A and Venture Funding Outlook and Competitive Landscape7$219Free
Chapter- 13: Company Profiles56$1,750Free
Chapter- 14: Appendix: Abbreviations4$125Free
Published - Oct-2012| Analyst - Shalini Shahani Dewan| Code - PHM118A

Report Highlights

The global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.

Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS